A transparent, point-by-point review of the claims made in the March 2026 letter to the editor regarding Dynamic Movement Intervention.
The response from DMI’s co-founders to the Paleg et al. (2026) commentary offers an opportunity to clarify several important points about the current state of evidence for Dynamic Movement Intervention. While the letter raises valid questions about scientific discourse, it also highlights ongoing challenges in establishing a robust evidence base for this approach.
Five years after its introduction in 2021, DMI remains without published randomized controlled trials or other high-level evidence demonstrating its effectiveness beyond a single conference abstract. This places the intervention at Sackett Level 5 — the lowest tier in evidence-based medicine hierarchies.
A structured review of the main points raised in the March 2026 letter to the editor.
The letter asserts that DMI differs significantly from CME and Neurodevelopmental Treatment in both structure and scientific rationale. However, the founders’ own prior statements describe DMI as “an evolution of CME” that uses “similar exercises” with added “tweaks.” Both approaches were developed by the same individuals who practiced CME/MEDEK for over two decades before launching DMI in 2021.
The core handling techniques — distal support, gravity challenge, and provoking absent milestones — remain consistent with established CME methodology. This raises legitimate questions about whether the “distinct” positioning is primarily a branding distinction rather than a fundamentally new intervention framework.
The letter suggests that meaningful commentary requires completion of DMI courses, direct communication with founders, session observation, and review by trained practitioners. While domain knowledge is valuable, science has long operated on the principle that claims should be evaluable based on published data and logical reasoning — not restricted to those with proprietary training.
This perspective aligns with standard scientific practice where methods are assessed through transparent, replicable evidence rather than insider access.
A single 2022 conference abstract describing two children with spinal muscular atrophy type 1 who received DMI following gene replacement therapy. The reported gains are heavily confounded by the concurrent disease-modifying treatment. No randomized trials, no control groups, and no peer-reviewed publications have emerged in the intervening years.
"To date, there is no published research on DMI."
"We are only 2 years old and that is why there isn’t any research."
One registered trial (DMI vs Bobath) — results not yet published.
Insurance coverage currently exists because DMI is billed under general physical/occupational therapy codes, not because specific efficacy has been demonstrated for this branded approach. Families often pay substantial out-of-pocket costs for intensive programs.
The letter references Kleim & Jones on experience-dependent plasticity and positions DMI within the ICF framework and dynamic systems theory. However, excerpts from DMI training materials and session descriptions emphasize therapist-directed handling, tone modification, primitive reflex integration, and automatic motor pattern development — concepts more closely aligned with mid-20th-century hierarchical facilitation models than contemporary task-specific, child-initiated, high-repetition functional training.
Current best-practice recommendations (including those from the authors cited in the letter) emphasize active, meaningful, child-led practice with high repetition in functional contexts. The degree to which DMI aligns with these principles remains an open question for further investigation.
No published safety data specific to DMI currently exists. Children with cerebral palsy and associated osteopenia are known to be at elevated fracture risk; any intensive handling approach warrants careful monitoring. Ethical practice requires transparent discussion of both potential benefits and risks with families.
$800 per 16-hour certification course. Over 3,300 therapists trained globally. The letter expresses concern about potential impacts on funding and grants. Independent, preregistered research with appropriate controls remains the gold standard for establishing credibility with payers, families, and the broader clinical community.
"DMI, introduced in 2021, has no published empirical evidence beyond a single conference abstract. Thus, both interventions remain at Sackett Level 5 — no evidence."
The Paleg et al. commentary represents a rigorous, literature-based analysis by internationally recognized experts in pediatric neurorehabilitation. The response from DMI leadership presents an alternative viewpoint that merits consideration alongside the published evidence.
A note on the individuals shaping this important conversation.
A Note on Scientific Discourse
The same letter that emphasizes the importance of specialized expertise simultaneously positions an individual with limited independent research credentials as a primary voice. This contrast underscores the value of transparent, evidence-based dialogue where claims can be evaluated on their merits by the broader scientific community.
Informed decision-making requires access to the full picture — including what is known and what remains unknown.
The current evidence landscape — or rather, the significant gaps within it — calls for continued rigorous investigation and open scientific dialogue.